Modern Approaches for Optimal Management of Dry Eye Disease

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss the prevalence of dry eye disease (DED) and how it can impact the quality of life for patients.

Experts discuss the impact of dry eye disease (DED) on coexisting ocular conditions and their clinical experience managing these patients.

Experts offer their clinical perspectives on the use of dry eye questionnaires as a method of screening for dry eye disease (DED).

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss their preferred clinical diagnostic tools and tests to evaluate patients for dry eye disease (DED) and strategies for educating patients on their results.

Experts discuss various treatment approaches for patients with dry eye disease (DED). They also highlight the challenges and drawbacks of using artificial tears to treat DED.

Kelly K. Nichols, OD, MPH, PhD, discusses various anti-inflammatory treatment options for dry eye disease (DED), such as cyclosporine, lifitegrast, and varenicline. In addition, Cynthia Matossian, MD, FACS, provides an overview of the mechanism of action of lifitegrast and how it differs from cyclosporine.

Experts discuss key factors to consider when using anti-inflammatory agents to treat dry eye disease (DED).

Kelly K. Nichols, OD, MPH, PhD, and Crystal Brimer, OD, provide their clinical advice on managing patients with overlapping eye diseases that need surgical treatment.

Cynthia Matossian, MD, FACS, provides her clinical advice on developing a treatment algorithm for patients with dry eye disease (DED).

Experts offer their clinical expertise on managing patients with dry eye disease (DED) with concurrent procedural and pharmacological therapies and the importance of individualized care.

Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss three new FDA-approved therapies for the treatment of dry eye disease (DED).

Crystal Brimer, OD, and Kelly K. Nichols, OD, MPH, PhD, discuss two treatments, AZR-MD-001 and Reproxalap, that are in the pipeline to treat patients with dry eye disease (DED).

Experts discuss their clinical approaches for co-managing patients with dry eye disease and how they educate patients and their providers about the disease.

Experts conclude their discussion sharing clinical peals on the management of dry eye disease (DED) and how providers may invest in their practice to better screen and treat their patients.